With respect to DNA repair genes, low ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group −1) expression has been associated with a better outcome upon platinum compounds initially in patients with ovarian cancer [2] and later in patients with NSCLC [3-11]. Here, ERCC1 is linked to ovarian carcinoma.